Albin H, Vincon G, Lalague M C, Couzigou P, Amouretti M
Eur J Clin Pharmacol. 1986;30(4):493-4. doi: 10.1007/BF00607967.
Twelve, healthy fasting, subjects received 200 mg cimetidine orally either with water or 1 g sucralfate in a randomized, single dose, two-way crossover study. Blood samples were taken for 12 h and urine was collected for 24 h. Cimetidine in plasma and urine was analysed by HPLC. There was no significant difference between the two treatments in peak plasma concentration, time to peak plasma concentration, area under the plasma concentration-time curve and urinary excretion. The results indicate that sucralfate did not reduce the bioavailability of cimetidine.
在一项随机、单剂量、双向交叉研究中，12名健康的空腹受试者口服200毫克西咪替丁，服药时分别用水送服或搭配1克硫糖铝。在12小时内采集血样，并在24小时内收集尿液。通过高效液相色谱法分析血浆和尿液中的西咪替丁。两种治疗方法在血浆峰浓度、达峰时间、血浆浓度-时间曲线下面积和尿排泄方面均无显著差异。结果表明，硫糖铝不会降低西咪替丁的生物利用度。
